Memphasys Ltd (AU:MEM)
ASX:MEM
Top Page
Memphasys Ltd
(Sydney:MEM)
Select Model
Select Model
Rating:45Neutral
Price Target:
AU$0.01
▲(0.00% Upside)
Action:ReiteratedDate:10/19/25
The overall score of 45 for Memphasys Ltd is primarily driven by weak financial performance, with significant losses and negative cash flows overshadowing strong revenue growth. Valuation concerns due to a negative P/E ratio further weigh on the score, while limited technical data keeps the analysis neutral.
Positive Factors
Revenue Growth
The strong revenue growth indicates increasing demand for Memphasys's fertility technologies, suggesting successful market penetration and potential for future sales expansion.
Negative Factors
Profitability Challenges
Ongoing profitability issues may hinder Memphasys's ability to reinvest in growth and innovation, potentially impacting its long-term financial health and competitive position.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
The strong revenue growth indicates increasing demand for Memphasys's fertility technologies, suggesting successful market penetration and potential for future sales expansion.
Read all positive factors
Memphasys Ltd (MEM) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$12.81M
Dividend YieldN/A
Average Volume (3M)17.19M
Price to Earnings (P/E)―
Beta (1Y)-0.26
Revenue Growth-93.83%
EPS Growth20.00%
CountryAU
Employees24
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding2,847,233,600
10 Day Avg. Volume17,186,563
30 Day Avg. Volume17,186,563
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)2.50
Price to Sales (P/S)25.46
P/FCF Ratio-5.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Memphasys Ltd Business Overview & Revenue Model
Company Description
Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. It primarily develops Felix, a novel automated device f...
How the Company Makes Money
Memphasys generates revenue through the sale of its Felix devices and associated consumables to fertility clinics and laboratories around the world. The company also earns income from service contracts, training, and support services related to th...
Memphasys Ltd Financial Statement Overview
Summary
Income Statement
25
Negative
Balance Sheet
40
Negative
Cash Flow
20
Very Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 213.98K | 526.92K | 60.00K | 15.37K | 27.15K | 211.48K |
| Gross Profit | -804.54K | 431.06K | -1.57M | -824.86K | -922.60K | -48.00K |
| EBITDA | -2.79M | -2.57M | -4.24M | -2.36M | -1.39M | -1.14M |
| Net Income | -4.31M | -4.94M | -4.44M | -3.40M | -2.08M | -1.49M |
Balance Sheet | ||||||
| Total Assets | 10.45M | 11.02M | 12.43M | 14.67M | 14.12M | 14.58M |
| Cash, Cash Equivalents and Short-Term Investments | 411.43K | 298.30K | 277.80K | 637.83K | 311.83K | 2.00M |
| Total Debt | 4.63M | 5.11M | 4.81M | 6.37M | 5.56M | 5.36M |
| Total Liabilities | 6.43M | 5.65M | 5.59M | 7.28M | 6.47M | 5.97M |
| Stockholders Equity | 4.02M | 5.37M | 6.84M | 7.38M | 7.65M | 8.61M |
Cash Flow | ||||||
| Free Cash Flow | -2.97M | -2.41M | -3.87M | -3.23M | -2.61M | -2.96M |
| Operating Cash Flow | -2.96M | -2.41M | -3.23M | -1.41M | 311.82K | 47.25K |
| Investing Cash Flow | -253.40K | -673.28K | -711.05K | -1.98M | -3.08M | -3.00M |
| Financing Cash Flow | 3.11M | 3.15M | 3.54M | 3.75M | 1.03M | 2.99M |
Memphasys Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | AU$33.06M | -4.43 | -258.19% | ― | 306.88% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | AU$12.81M | -1.59 | -91.88% | ― | -93.83% | 20.00% | |
45 Neutral | AU$8.84M | -0.15 | 2844.96% | ― | ― | 46.28% | |
44 Neutral | AU$10.20M | -0.48 | 1068.18% | ― | ― | 31.87% | |
43 Neutral | AU$28.18M | -6.84 | -49.25% | ― | ― | ― | |
40 Underperform | AU$11.21M | -1.00 | -218.76% | ― | ― | ― |
* Healthcare Sector Average
AU:MEM
Memphasys Ltd
―
―
―
AU:1AI
Living Cell Technologies
0.02
<0.01
60.00%
AU:CMB
Regeneus Ltd.
0.41
0.13
46.43%
AU:AVE
Avecho Biotechnology Limited
0.01
0.00
0.00%
AU:1AD
AdAlta Ltd.
―
―
―
AU:CHM
Chimeric Therapeutics Ltd.
―
―
―
Memphasys Ltd Corporate Events
Memphasys Issues 26 Million Shares for Advisory and Service Fees Under Cleansing Notice
Dec 31, 2025
Memphasys Limited has issued 26 million fully paid ordinary shares at a deemed issue price of $0.003 per share as consideration for corporate advisory and other services, following shareholder approvals granted at its 20 November 2025 Annual Gener...
Memphasys Issues 27.5 Million Unquoted Options as Part of Capital Management
Dec 30, 2025
Memphasys Limited has notified the market of the issue of a total of 27.5 million unquoted equity securities, including 2.5 million options expiring on 5 November 2026 with an exercise price of $0.011, and 25 million new unquoted “Alignment ...
Memphasys Seeks ASX Quotation for 26 Million New Shares
Dec 30, 2025
Memphasys Limited has applied to the ASX for quotation of 26 million new fully paid ordinary shares under its existing issuer code MEM, reflecting the issue of additional securities previously flagged to the market. The new shares, dated 31 Decemb...
Memphasys Issues Over 13 Million New Shares in Director Placement and Fee Conversion
Dec 30, 2025
Memphasys has issued 13,253,620 fully paid ordinary shares on 19 December 2025, primarily related to director participation in a Tranche 2 placement and the conversion of directors’ fees into equity at an issue price or deemed issue price of...
Memphasys Secures Extended Convertible Note Terms from Major Shareholder
Dec 30, 2025
Memphasys Limited has extended the maturity date of its convertible notes with major long-term shareholder Peters Investments to 30 June 2026, giving the company more time and flexibility to manage its repayment obligations while maintaining the p...
Memphasys Issues Over 72 Million Unquoted Options Expiring in 2026
Dec 30, 2025
Memphasys Limited has notified the market of the issue of a new tranche of unquoted options, identified under ASX code MEMAX and expiring on 5 November 2026. The company will issue 72,708,332 of these unquoted options on 30 December 2025 as part o...
Memphasys Seeks ASX Quotation for 193 Million New Shares Following Entitlement Offer
Dec 30, 2025
Memphasys Limited has applied to the ASX for quotation of 193,055,540 new fully paid ordinary shares, expanding its listed capital base under the code MEM. The new shares arise from an entitlement offer and associated shortfall offer made under a ...
Memphasys Issues 48.3 Million Unquoted Options to Strengthen Capital Structure
Dec 30, 2025
Memphasys Limited has notified the market of the issue of 48,263,886 unquoted options (ASX code MEMAX), each exercisable at $0.011 and expiring on 5 November 2026. The large grant of options, effective 30 December 2025, signals a move to bolster i...
Memphasys Raises $1.12m to Accelerate Global Rollout of Felix Fertility System
Dec 29, 2025
Memphasys Limited has completed the placement of 193,055,540 shortfall shares at $0.003 each, together with 48,263,886 free attaching unlisted options, raising $579,166.62 and bringing total proceeds from its recent entitlement offer to about $1.1...
Memphasys Director Increases Equity Stake Through Share and Option Acquisitions
Dec 29, 2025
Memphasys Limited has disclosed a change in the securities interests of director Marjan Mikel, noting both direct and indirect holdings through entities associated with him. The filing details Mikel’s acquisition of 6,666,667 fully paid ordi...
Memphasys Wins CE Mark for Felix System, Triggering Global Commercial Rollout
Dec 28, 2025
Memphasys has secured CE Mark approval under the European Union Medical Device Regulation for its Felix™ automated sperm selection system, allowing commercial sale and clinical use across the European Economic Area and other CE-recognising j...
Memphasys Shares Halted Pending Key Regulatory Milestone Announcement
Dec 23, 2025
Memphasys Limited has requested and been granted a trading halt on its shares on the Australian Securities Exchange from the open of trading on 24 December 2025, with the halt to remain in place until either the release of a pending market announc...
Memphasys Wins First Major European IVF Supply Deal With Italy’s CFA
Dec 21, 2025
Memphasys has signed a five-year commercial supply agreement with Centro Fertilita Assistita (CFA) Italia, one of Italy’s largest private IVF groups, marking its first commercial contract in mainland Europe and a key step in its global rollo...
Memphasys Issues 25 Million Unquoted Alignment Options Under Existing Transactions
Dec 19, 2025
Memphasys Limited has notified the market of the issue of a total of 25 million unquoted Alignment Options in three tranches (6.5 million, 8.5 million and 10 million) on 19 December 2025. These options, which are not quoted and are not intended to...
Memphasys Issues 1.67 Million Unquoted Options Under Existing Arrangements
Dec 19, 2025
Memphasys Limited has issued 1,666,667 unquoted options (MEMAX) exercisable at $0.011 and expiring on 5 November 2026, as notified to the ASX in a new Appendix 3G filing dated 19 December 2025. The options, which arise from previously announced tr...
Memphasys Seeks ASX Quotation for 6.6 Million New Shares
Dec 19, 2025
Memphasys Limited has applied for quotation on the ASX of 6,586,953 new fully paid ordinary shares under the code MEM. The newly issued securities, which stem from a previously announced transaction, will expand the company’s quoted share ca...
Memphasys Seeks ASX Quotation for 6.7 Million New Shares
Dec 19, 2025
Memphasys Limited has applied to the ASX for quotation of 6,666,667 new fully paid ordinary shares under code MEM, with an issue date of 19 December 2025, pursuant to previously announced transactions. The move will expand the company’s quot...
Memphasys Secures Early Order for Felix™ Cartridges in the Middle East, Validating Strategy
Dec 18, 2025
Memphasys Limited has received an early order for 500 Felix™ cartridges from its key Middle East partner, International Technical Legacy (ITL), ahead of the product’s CE Mark approval. This accelerated purchase highlights strong demand...
Memphasys Restructures Leadership to Enhance Global Commercialization of Felix™ System
Dec 9, 2025
Memphasys Limited has announced a leadership restructure to support its shift towards a direct-selling global commercialization strategy for its Felix™ System. The restructure includes the redundancy of the CEO position and the departure of ...
Memphasys Accelerates Middle East Expansion with Direct Sales Strategy for Felix™ Device
Dec 8, 2025
Memphasys Limited is advancing the commercialisation of its Felix™ sperm-selection device through a direct sales strategy in the Middle East, focusing on converting clinical interest into purchasing behavior and recurring revenue. The strate...
Memphasys Ltd Reports 2025 AGM Results
Nov 20, 2025
Memphasys Ltd announced the results of its Annual General Meeting held on November 20, 2025. Several resolutions were passed, including the election of directors and the approval of issuing shares and options to various stakeholders. The outcomes ...
Memphasys Ltd Focuses on Felix Commercialisation
Nov 20, 2025
Memphasys Ltd, a company listed on the Australian Securities Exchange (ASX) under the ticker MEM, is focused on the commercialisation of its product, Felix. The company has released an investor presentation outlining its strategic focus on product...
Memphasys Limited Sharpens Focus on Felix™ System Amid Strategic Realignment
Nov 20, 2025
Memphasys Limited has undergone significant strategic realignment, focusing on the commercial success of its Felix™ system. The company has shifted from a traditional distributor model to engaging with partners for better market adoption and...
Memphasys Limited Issues New Shares to Bolster IVF Technology Expansion
Nov 11, 2025
Memphasys Limited has issued 33,333,333 fully paid ordinary shares at $0.003 per share to professional and sophisticated investors, as part of a placement announced in September 2025. This move is in line with the company’s strategy to scale...
Memphasys Limited Announces Quotation of New Securities on ASX
Nov 11, 2025
Memphasys Limited has announced the application for the quotation of 33,333,333 fully paid ordinary securities on the Australian Securities Exchange (ASX). This move is part of a previously announced transaction, and it signifies a strategic step ...
Memphasys Ltd Issues Unquoted Securities
Nov 10, 2025
Memphasys Ltd has announced the issuance of 45,115,338 unquoted securities, specifically options expiring on November 5, 2026. This move is part of previously announced transactions and is not intended to be quoted on the ASX, potentially impactin...
Memphasys Ltd Announces Quotation of New Securities on ASX
Nov 10, 2025
Memphasys Ltd has announced the quotation of 180,460,810 fully paid ordinary securities on the Australian Securities Exchange (ASX) as of November 10, 2025. This move is part of a previously announced transaction and is expected to enhance the com...
Memphasys Completes Entitlement Offer to Boost Felix™ Commercialization
Nov 9, 2025
Memphasys Limited has successfully completed its Entitlement Offer, raising approximately $541,382.43 through the issuance of new shares and options. The funds will be used to advance the commercialization of the Felix™ System, including obt...
Memphasys Limited Advances Commercialisation of Felix™ System with Strategic Milestones
Oct 31, 2025
Memphasys Limited has completed a strategic shift to focus exclusively on the commercialisation of its Felix™ System, marking a transition from RD to commercial execution. The company has achieved significant milestones, including a five-yea...
Memphasys Expands Indian Market Presence with New Supply Agreement
Oct 27, 2025
Memphasys Limited has signed a non-exclusive supply agreement with Andrology Center Coimbatore to expand its Felix™ System’s presence in the Indian market. This agreement marks a strategic shift to a go-direct commercial strategy, aimi...
Memphasys Limited Announces Board Changes and Compliance Assurance
Oct 27, 2025
Memphasys Limited announced changes in its board of directors, with Mr. Mathew Watkins appointed and Mr. David Ali ceasing as directors. The company acknowledged an administrative oversight in the timely filing of director interest notices but ass...
Memphasys Strengthens Presence in Japan with Repeat Felix ™ Order
Oct 23, 2025
Memphasys Limited has secured a repeat order for 200 Felix ™ cartridges from the Nishitan ART Clinic Group in Japan, highlighting the growing adoption of its technology in the world’s largest IVF market. This order marks a significant ...
Memphasys Ltd Announces 2025 AGM Details and Embraces Digital Engagement
Oct 21, 2025
Memphasys Ltd has announced the details for its 2025 Annual General Meeting (AGM), which will be held physically in Sydney. The company is adapting to modern communication methods by providing meeting materials online and encouraging electronic vo...
Memphasys Limited Announces Strategic Board Changes Amid Commercialisation Drive
Oct 20, 2025
Memphasys Limited has announced several board changes as it pivots towards the commercialisation of its Felix ™ System. Dr. David Ali will step down as Executive Director to focus on his role as CEO, emphasizing operational execution as the ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.